» Articles » PMID: 37998389

Gut Microbiota, Inflammatory Bowel Disease, and Cancer: The Role of Guardians of Innate Immunity

Overview
Journal Cells
Publisher MDPI
Date 2023 Nov 24
PMID 37998389
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammatory bowel diseases (IBDs) are characterized by a persistent low-grade inflammation that leads to an increased risk of colorectal cancer (CRC) development. Several factors are implicated in this pathogenetic pathway, such as innate and adaptive immunity, gut microbiota, environment, and xenobiotics. At the gut mucosa level, a complex interplay between the immune system and gut microbiota occurs; a disequilibrium between these two factors leads to an alteration in the gut permeability, called 'leaky gut'. Subsequently, an activation of several inflammatory pathways and an alteration of gut microbiota composition with a proliferation of pro-inflammatory bacteria, known as 'pathobionts', take place, leading to a further increase in inflammation. This narrative review provides an overview on the principal Pattern Recognition Receptors (PRRs), including Toll-like receptors (TLRs) and NOD-like receptors (NLRs), focusing on their recognition mechanisms, signaling pathways, and contributions to immune responses. We also report the genetic polymorphisms of TLRs and dysregulation of NLR signaling pathways that can influence immune regulation and contribute to the development and progression of inflammatory disease and cancer.

Citing Articles

Circulating RNA Markers Associated with Adenoma-Carcinoma Sequence in Colorectal Cancer.

Kim L, Han J, Kim T, Park J, Lee J, Kim J Int J Mol Sci. 2025; 26(4).

PMID: 40003985 PMC: 11855670. DOI: 10.3390/ijms26041518.


Leaky Gut Syndrome Along With Clostridium perfringens Bacteremia in a Neurodegenerative Disease Patient: A Case Report.

Usuda D, Sugita M, Shen P, Umehara T, Kitamoto T Cureus. 2025; 16(12):e75290.

PMID: 39776697 PMC: 11703780. DOI: 10.7759/cureus.75290.


Toll-like receptor 4 plays a vital role in irritable bowel syndrome: a scoping review.

Wan X, Wang L, Wang Z, Wan C Front Immunol. 2025; 15:1490653.

PMID: 39749341 PMC: 11693509. DOI: 10.3389/fimmu.2024.1490653.


Modulation of Orosomucoid-like Protein 3 Activity in the Management of Inflammatory Bowel Disease.

Malicevic U, Rai V, Skrbic R, Agrawal D J Biotechnol Biomed. 2024; 7(4):433-444.

PMID: 39619146 PMC: 11606571. DOI: 10.26502/jbb.2642-91280167.


Fecal microbiota and metabolites in the pathogenesis and precision medicine for inflammatory bowel disease.

Ju L, Suo Z, Lin J, Liu Z Precis Clin Med. 2024; 7(3):pbae023.

PMID: 39381014 PMC: 11459260. DOI: 10.1093/pcmedi/pbae023.


References
1.
Hugot J, Chamaillard M, Zouali H, Lesage S, Cezard J, Belaiche J . Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411(6837):599-603. DOI: 10.1038/35079107. View

2.
Hoffmann P, Lamerz D, Hill P, Kirchner M, Gauss A . Gene Polymorphisms of NOD2, IL23R, PTPN2 and ATG16L1 in Patients with Crohn's Disease: On the Way to Personalized Medicine?. Genes (Basel). 2021; 12(6). PMC: 8227795. DOI: 10.3390/genes12060866. View

3.
Kuemmerle-Deschner J, Hansmann S, Wulffraat N, Vastert S, Hens K, Anton J . Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative. Ann Rheum Dis. 2017; 77(3):319-327. DOI: 10.1136/annrheumdis-2017-211904. View

4.
Fukata M, Shang L, Santaolalla R, Sotolongo J, Pastorini C, Espana C . Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis. 2011; 17(7):1464-73. PMC: 3117047. DOI: 10.1002/ibd.21527. View

5.
Pagliari D, Saviano A, Newton E, Serricchio M, Dal Lago A, Gasbarrini A . Gut Microbiota-Immune System Crosstalk and Pancreatic Disorders. Mediators Inflamm. 2018; 2018:7946431. PMC: 5833470. DOI: 10.1155/2018/7946431. View